Introduction

If joint pain or stiffness is limiting what you can do, one of the most important early questions is whether surgery is actually necessary. For many people with localised cartilage wear and smaller defects, an ultrasound-guided injection may be a reasonable first step — one that preserves the joint without theatre, incisions, or a long recovery. This article explains the ChondroFiller injection in plain terms, with realistic expectations throughout.

What Is ChondroFiller?

ChondroFiller is a CE-marked (Class III medical device) acellular, cell-free, Type I collagen hydrogel manufactured by Meidrix Biomedicals in Germany. When delivered into a cartilage defect, the two-component system self-gels within approximately three to five minutes, forming a stable scaffold that fills the defect contour without requiring sutures or fixation. The CE marking and the published clinical outcome data — including improvements in knee and hip function scores — belong to ChondroFiller as the device.

The scaffold is cell-free by design. Rather than containing cells, it acts as a chemotactic matrix: once in place it attracts the patient's own progenitor cells from the surrounding synovium and subchondral bone, supporting endogenous cartilage repair over a period of months to years. Clinical evidence suggests improvement in patient-reported outcomes across multiple joints, though responses vary and cartilage regrowth cannot be guaranteed.

Key Features of the Minimally Invasive Injection

The ChondroFiller injection is a non-surgical, outpatient procedure. The scaffold is delivered using an ultrasound-guided fine needle — no incisions, no general anaesthetic, and no overnight stay. This tends to mean fewer complications and a more straightforward recovery than surgical alternatives.

• Outpatient, non-surgical — no theatre required
• Ultrasound guidance ensures accurate delivery to the defect site
• Self-gelling scaffold adheres without stitches
• Cell-free formulation that works with the body's own repair mechanisms
• Single procedure in most cases

What the Evidence Shows

ChondroFiller's clinical evaluation report draws on multiple manufacturer-sponsored studies and independent literature. In the knee, International Knee Documentation Committee (IKDC) scores have consistently improved by approximately 30 points over 12 to 36 months. In the hip, modified Harris Hip Scores (mHHS) have improved by more than 30 points. Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) scores in knee and hip studies have reached around 80 and above, indicating good-quality defect fill and tissue integration.

A 2023 study of trapeziometacarpal (thumb-base) osteoarthritis reported significant improvements in pain and grip strength following ChondroFiller treatment (Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U., 2023. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage). These are encouraging findings, though responses vary and the evidence base continues to develop.

ChondroFiller Injection Versus Liquid Cartilage Surgery

Patients sometimes encounter the term Liquid Cartilage alongside ChondroFiller and assume they refer to the same thing. They do not.

The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure suited to accessible joints and smaller defects. Liquid Cartilage is a distinct surgical protocol — the Lee Liquid Cartilage Protocol developed by Professor Paul Y. F. Lee — a keyhole (arthroscopic) procedure performed in theatre under anaesthetic. In addition to delivering the ChondroFiller scaffold, the surgical protocol incorporates biological adjuncts such as platelet-rich fibrin or platelet-rich plasma, and where indicated, the patient's own mesenchymal stem cells (from bone-marrow concentrate or micro-fragmented fat). Liquid Cartilage is reserved for larger or more complex defects in load-bearing joints where an injection alone would be insufficient.

If assessment confirms that a straightforward non-surgical injection is appropriate, ChondroFiller is the relevant pathway. If the defect is larger, in a heavily loaded joint, or requires surgical preparation, the Liquid Cartilage protocol is the more appropriate option. A thorough clinical assessment is always the starting point.

Considerations and Suitability

Whether the ChondroFiller injection is suitable depends on the joint involved, the size and grade of the cartilage defect, the patient's overall joint health, and realistic expectations. It is not appropriate for end-stage arthritis or bone-on-bone joint disease. It is best understood as a joint-preservation option — one that may slow the progression of wear and support biological repair rather than reversing established arthritis.

Assessment at the London Cartilage Clinic begins with imaging and a detailed clinical review to determine whether the ChondroFiller injection, the Liquid Cartilage surgical protocol, or a different management pathway is the right recommendation for that individual.

Conclusion

The ChondroFiller injection offers a non-surgical, outpatient route to addressing localised cartilage wear in suitable patients. The self-gelling scaffold requires no stitches and the recovery is straightforward. It is not a cure and cannot reverse arthritis, but in appropriately selected patients the published evidence suggests clinically meaningful improvements in pain and function. For those with larger or more complex defects, the Liquid Cartilage surgical protocol may be the more suitable path. The London Cartilage Clinic provides assessment and access to both pathways. If you have persistent joint pain, seeking specialist advice early is the most productive first step.

References

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.